StockData

Fulgent Genetics vs Grail

FLGT and GRAL side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How FLGT and GRAL compare

Grail is the larger company, worth 7.1 times as much as Fulgent Genetics ($4.7B against $666M).

Grail grew revenue faster over the last twelve months (23.1% versus 6.8% for Fulgent Genetics).

Fulgent Genetics keeps more of each dollar of sales as profit, with a net margin of −26.0% compared with −237% at Grail.

Grail scores higher on the StockData Score (10 against 7 for Fulgent Genetics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricFLGTGRAL
Size and price
Market cap$666M$4.7B
Share price$24.21$105.88
Change, 1 year−16.8%33.0%
Change, 5 years−75.2%–
Beta (5Y)0.492.06
Employees1,300910
StockData Score
Total score710 (better)
Valuation score3 (better)1
Growth score02 (better)
Performance score11
Health score36 (better)
Dividend score00
Valuation
P/S2.1× (better)28.6×
P/B0.7× (better)1.9×
FCF yield−15.6%−6.3% (better)
Fair value$45.28–
Margin of safety46.5%–
Growth
Revenue growth (TTM)6.8%23.1% (better)
Revenue growth, 5Y average−5.2%–
Profitability
Gross margin35.6%–
Operating margin−37.7% (better)−338%
Net margin−26.0% (better)−237%
FCF margin−32.0% (better)−179%
Return on equity−8.0% (better)−16.1%
Return on invested capital−10.9% (better)−26.0%
Financial health
Debt / equity0.00 (better)0.00
Interest coverage−1019.0×–
Current ratio6.3410.95 (better)
Altman Z-score5.25 (better)4.06
Piotroski F-score45 (better)
Dividends and buybacks
Buyback yield9.6%–
Shareholder yield9.6% (better)0.00%
Ownership
Held by institutions57.0%87.6%
Held by insiders39.5%11.0%
Insider net buying, 12 months−$286K (better)−$38.3M
Short interest, % of float12.1%20.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.